Cited by 599Viral Infections and Immunology ResearchSARS-CoV-2 and COVID-19 ResearchPharmacovigilance and Adverse Drug Reactions

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel

Open access

Mevorach, Dror, Anis, Emilia, Cedar, Noa, Bromberg, Michal, Haas, Eric J., Nadir, Eyal, Olsha-Castell, Sharon, Arad, Dana, Hasin, Tal, Levi, Nir, Asleh, Rabea, Amir, Offer, Meir, Karen, Cohen, Dotan, Dichtiar, Rita, Novick, Deborah, Hershkovitz, Yael, Dagan, Ron, Leitersdorf, Iris, Ben-Ami, Ronen, Miskin, Ian, Saliba, Walid, Muhsen, Khitam, Levi, Yehezkel, Green, Manfred S., Keinan-Boker, Lital, Alroy-Preis, Sharon·2021·New England Journal of Medicine

DOI 10.1056/nejmoa2109730PMC PMC8531987

Open this paper in CoChat — free account

Abstract

BACKGROUND: Approximately 5.1 million Israelis had been fully immunized against coronavirus disease 2019 (Covid-19) after receiving two doses of the BNT162b2 messenger RNA vaccine (Pfizer-BioNTech) by May 31, 2021. After early reports of myocarditis during adverse events monitoring, the Israeli Ministry of Health initiated active surveillance. METHODS: We retrospectively reviewed data obtained from December 20, 2020, to May 31, 2021, regarding all cases of myocarditis and categorized the information using the Brighton Collaboration definition. We analyzed the occurrence of myocarditis by computing the risk difference for the comparison of the incidence after the first and second vaccine doses (21 days apart); by calculating the standardized incidence ratio of the observed-to-expected incidence within 21 days after the first dose and 30 days after the second dose, independent of certainty of diagnosis; and by calculating the rate ratio 30 days after the second dose as compared with unvaccinated persons. RESULTS: Among 304 persons with symptoms of myocarditis, 21 had received an alternative diagnosis. Of the remaining 283 cases, 142 occurred after receipt of the BNT162b2 vaccine; of these cases, 136 diagnoses were definitive or probable. The clinical presentation was judged to be mild in 129 recipients (95%); one fulminant case was fatal. The overall risk difference between the first and second doses was 1.76 per 100,000 persons (95% confidence interval [CI], 1.33 to 2.19), with the largest difference among male recipients between the ages of 16 and 19 years (difference, 13.73 per 100,000 persons; 95% CI, 8.11 to 19.46). As compared with the expected incidence based on historical data, the standardized incidence ratio was 5.34 (95% CI, 4.48 to 6.40) and was highest after the second dose in male recipients between the ages of 16 and 19 years (13.60; 95% CI, 9.30 to 19.20). The rate ratio 30 days after the second vaccine dose in fully vaccinated recipients, as compared with unvaccinated persons, was 2.35 (95% CI, 1.10 to 5.02); the rate ratio was again highest in male recipients between the ages of 16 and 19 years (8.96; 95% CI, 4.50 to 17.83), with a ratio of 1 in 6637. CONCLUSIONS: The incidence of myocarditis, although low, increased after the receipt of the BNT162b2 vaccine, particularly after the second dose among young male recipients. The clinical presentation of myocarditis after vaccination was usually mild.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa2109730

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data
Haas, E. J., Angulo, F. J., McLaughlin, J. M., Anis, E., Singer, S. R., Khan, F., Brooks, N., Smaja, M., Mircus, G., Pan, K., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00947-8 · Cited by 1,564
Self-citation
Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
Barda, N., Dagan, N., Ben-Shlomo, Y., Kepten, E., Waxman, J., Ohana, R., Hernán, M. A., Lipsitch, M., Kohane, I., Netzer, D., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110475 · Cited by 1,027
Myocarditis after Covid-19 Vaccination in a Large Health Care Organization
Witberg, G., Barda, N., Hoss, S., Richter, I., Wiessman, M., Aviv, Y., Grinberg, T., Auster, O., Dagan, N., Balicer, R. D., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110737 · Cited by 613
Myocarditis and pericarditis after immunization: Gaining insights through the Vaccine Adverse Event Reporting System
Mei, R., Raschi, E., Forcesi, E., Diemberger, I., Ponti, F. D., & Poluzzi, E. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.09.054 · Cited by 84
Surveillance Guidelines for Smallpox Vaccine (vaccinia) Adverse Reactions
Casey, C., Vellozzi, C. J., Mootrey, G. T., Chapman, L. E., McCauley, M. M., Roper, M. H., Damon, I. K., & Swerdlow, D. L. (2006) · PsycEXTRA Dataset · doi:10.1037/e506942006-001 · Cited by 58
Update: Cardiac-Related Events During the Civilian Smallpox Vaccination Program— United States, 2003
(2003) · JAMA · doi:10.1001/jama.290.1.31 · Cited by 41

Flagged first, then by citations

Show all 7 references

Research works printed but not linked: 1

Sahai H Khurshid A. Statistics in epidemiology: methods techniques and applications. Boca Raton FL: CRC Press 1996.

Sorted by citations

Items 101–200 of 598

Molecular Mimicry of the Viral Spike in the SARS-CoV-2 Vaccine Possibly Triggers Transient Dysregulation of ACE2, Leading to Vascular and Coagulation Dysfunction Similar to SARS-CoV-2 Infection
Devaux, C. A., & Camoin‐Jau, L. (2023) · Viruses · doi:10.3390/v15051045 · Cited by 34
COVID-19 and Myocarditis: Review of Clinical Presentations, Pathogenesis and Management
Lovell, J. P., Division of Cardiology, D. O. M., Čiháková, D., Department of Pathology, J. H. U. O. M., W. Harry Feinstone Department of Molecular Microbiology and Immunology, J. H. U. B. S. O. P. H., Gilotra, N. A., & Division of Cardiology, D. O. M. (2022) · Heart International · doi:10.17925/hi.2022.16.1.20 · Cited by 29
Myocarditis following COVID-19 vaccination: incidence, mechanisms, and clinical considerations
Power, J. R., Keyt, L. K., & ADLER, E. D. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2022.2066522 · Cited by 32
COVID‐19: Clinical status of vaccine development to date
Kumar, S., Basu, M., Ghosh, P., Ansari, A., & Ghosh, M. K. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15552 · Cited by 32
Hypersensitivity Myocarditis after COVID-19 mRNA Vaccination
Frustaci, A., Verardo, R., Galea, N., Lavalle, C., Bagnato, G., Scialla, R., & Chimenti, C. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11061660 · Cited by 29
COVID-19 Vasculitis and vasculopathy-Distinct immunopathology emerging from the close juxtaposition of Type II Pneumocytes and Pulmonary Endothelial Cells
Giryes, S., Bragazzi, N. L., Bridgewood, C., Marco, G. D., & McGonagle, D. (2022) · Seminars in Immunopathology · doi:10.1007/s00281-022-00928-6 · Cited by 32
Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults
Niyomnaitham, S., Toh, Z. Q., Wongprompitak, P., Jansarikit, L., Srisutthisamphan, K., Sapsutthipas, S., Jantraphakorn, Y., Mingngamsup, N., Licciardi, P. V., & Chokephaibulkit, K. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2091865 · Cited by 27
Assessment of Myocardial 18F-FDG Uptake at PET/CT in Asymptomatic SARS-CoV-2–vaccinated and Nonvaccinated Patients
Nakahara, T., Iwabuchi, Y., Miyazawa, R., Tonda, K., Shiga, T., Strausś, H. W., Antoniades, C. A., Narula, J., & Jinzaki, M. (2023) · Radiology · doi:10.1148/radiol.230743 · Cited by 28
Benefit-risk assessment of COVID-19 vaccine, mRNA (Comirnaty) for age 16–29 years
Funk, P. R., Yogurtcu, O. N., Forshee, R. A., Anderson, S. A., Marks, P. W., & Yang, H. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.03.030 · Cited by 27
Myocarditis Following a Third BNT162b2 Vaccination Dose in Military Recruits in Israel
Friedensohn, L., Levin, D., Fadlon-Derai, M., Gershovitz, L., Fink, N., Glassberg, E., & Gordon, B. (2022) · JAMA · doi:10.1001/jama.2022.4425 · Cited by 26
Myocarditis Cases After mRNA-Based COVID-19 Vaccination in the US—Reply
Oster, M. E., Shay, D. K., & Shimabukuro, T. T. (2022) · JAMA · doi:10.1001/jama.2022.5134 · Cited by 26
From Immunogen to COVID-19 vaccines: Prospects for the post-pandemic era
Miao, G., Chen, Z., Cao, H., Wu, W., Chu, X., Liu, H., Zhang, L., Zhu, H., Cai, H., Lu, X., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114208 · Cited by 27
The COVID-19 pandemic in children and young people during 2020-2021: A complex discussion on vaccination
Rudan, I., Adeloye, D., Katikireddi, S. V., Murray, J., Simpson, C. R., Shah, S. A., Robertson, C., & Sheikh, A. (2021) · Journal of Global Health · doi:10.7189/jogh.11.01011 · Cited by 24
Myocarditis after RNA-based vaccines for coronavirus.
Cordero, A., Morallón, D. C., Escribano, D., Quintanilla, M. A., López-Ayala, J. M., Pérez-Berbel, P., & Bertomeu‐González, V. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.01.037 · Cited by 25
Myocarditis after COVID‐19 mRNA vaccination: A systematic review of case reports and case series
Park, D. Y., An, S., Kaur, A., Malhotra, S., & Vij, A. (2022) · Clinical Cardiology · doi:10.1002/clc.23828 · Cited by 25
Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy
Walle, T., Bajaj, S., Kraske, J. A., Rösner, T., Cussigh, C. S., Kälber, K. A., Müller, L. J., Strobel, S. B., Burghaus, J., Kallenberger, S. M., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00398-7 · Cited by 24
Risk of myopericarditis following COVID ‐19 mRNA vaccination in a large integrated health system: A comparison of completeness and timeliness of two methods
Sharff, K. A., Dancoes, D. M., Longueil, J. L., Johnson, E. S., & Lewis, P. F. (2022) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5439 · Cited by 24
Multisystem Inflammatory Syndrome Following SARS-CoV-2 Vaccination in Two Children
Karatzios, C., Scuccimarri, R., Chédeville, G., Basfar, W., Bullard, J., & Stein, D. R. (2022) · PEDIATRICS · doi:10.1542/peds.2021-055956 · Cited by 24
COVID-19 Myocarditis: An Emerging Clinical Conundrum
Okor, I., Bob‐Manuel, T., Price, J. H., Sleem, A., Amoran, O., Kelly, J. M., Ekerete, M. F., Bamgbose, M. O., Bolaji, O. A., & Krim, S. R. (2022) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2022.101268 · Cited by 25
The Coming of Age of Nucleic Acid Vaccines during COVID-19
Rando, H. M., Lordan, R., Kolla, L., Sell, E., Lee, A. J., Wellhausen, N., Naik, A. S., Kamil, J. P., Gitter, A., Greene, C. S., et al. (2023) · mSystems · doi:10.1128/msystems.00928-22 · Cited by 30
Development of myocarditis and pericarditis after COVID‐19 vaccination in children and adolescents: A systematic review
Fatima, M., Khan, M. H. A., Ali, M. S., Osama, M., Cheema, H. A., Ahmed, A., Nisar, A., Murad, M. W., Farooq, H., Rehman, M. A. U., et al. (2023) · Clinical Cardiology · doi:10.1002/clc.23965 · Cited by 24
Myocarditis or Pericarditis Following mRNA COVID-19 Vaccination
Weintraub, E., Oster, M. E., & Klein, N. P. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.18512 · Cited by 23
Catecholamines Are the Key Trigger of COVID-19 mRNA Vaccine-Induced Myocarditis: A Compelling Hypothesis Supported by Epidemiological, Anatomopathological, Molecular, and Physiological Findings
Cadegiani, F. (2022) · Cureus · doi:10.7759/cureus.27883 · Cited by 25
Differential patterns of cross-reactive antibody response against SARS-CoV-2 spike protein detected for chronically ill and healthy COVID-19 naïve individuals
Jaago, M., Rähni, A., Pupina, N., Pihlak, A., Sadam, H., Tuvikene, J., Avarlaid, A., Planken, A., Planken, M., Haring, L., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-20849-6 · Cited by 23
Changes of ECG parameters after BNT162b2 vaccine in the senior high school students
Chiu, S., Chen, Y., Hsu, C.-C., Hua, Y., Tseng, W., Lu, C., Lin, M., Chen, C., Wu, M., Chen, Y., et al. (2023) · European Journal of Pediatrics · doi:10.1007/s00431-022-04786-0 · Cited by 23
COVID-19 Therapeutics: Use, Mechanism of Action, and Toxicity (Vaccines, Monoclonal Antibodies, and Immunotherapeutics)
Chary, M. A., Barbuto, A. F., Izadmehr, S., Tarsillo, M., Fleischer, E., & Burns, M. M. (2023) · Journal of Medical Toxicology · doi:10.1007/s13181-023-00931-9 · Cited by 25
Personalized Management of Myocarditis and Inflammatory Cardiomyopathy in Clinical Practice
Tymińska, A., Ozierański, K., Skwarek, A., Kapłon‐Cieślicka, A., Baritussio, A., Grabowski, M., Marcolongo, R., & Caforio, A. L. P. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12020183 · Cited by 27
CMR Imaging 6 Months After Myocarditis Associated with the BNT162b2 mRNA COVID-19 Vaccine
Amir, G., Rotstein, A., Razon, Y., Beer, G., Barak‐Corren, Y., Godfrey, M. E., Lakovsky, Y., Yaeger-Yarom, G., Yarden‐Bilavsky, H., & Birk, E. (2022) · Pediatric Cardiology · doi:10.1007/s00246-022-02878-0 · Cited by 22
COVID-19 vaccine-associated myocarditis
Morgan, M. C., Atri, L., Harrell, S., AlJaroudi, W., & Berman, A. E. (2022) · World Journal of Cardiology · doi:10.4330/wjc.v14.i7.382 · Cited by 23
Cardiovascular safety of COVID-19 vaccines in real-world studies: a systematic review and meta-analysis
Chang, Y., Lv, G., Liu, C., Huang, E., & Luo, B. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2150169 · Cited by 22
Development of Autoantibodies Following BNT162b2 mRNA COVID-19 Vaccination and Their Association with Disease Flares in Adult Patients with Autoimmune Inflammatory Rheumatic Diseases (AIIRD) and the General Population: Results of 1-Year Prospective Follow-Up Study
Gazitt, T., Eviatar, T., Shear, J., Meidan, R., Furer, V., Feld, J., Haddad, A., Elias, M., Hijazi, N., Stein, N., et al. (2023) · Vaccines · doi:10.3390/vaccines11020476 · Cited by 22
Update on COVID‐19 vaccination in pediatric solid organ transplant recipients
Dulek, D. E., Ardura, M. I., Green, M., Michaels, M. G., Chaudhuri, A., Vásquez, L., Danziger‐Isakov, L. A., Posfay-Barbe, K. M., McCulloch, M., L’Huillier, A. G., et al. (2022) · Pediatric Transplantation · doi:10.1111/petr.14235 · Cited by 21
Self-citation
Severe Acute Myocarditis after the Third (Booster) Dose of mRNA COVID-19 Vaccination
Mengesha, B., Asenov, A., Raccah, B. H., Amir, O., Pappo, O., & Asleh, R. (2022) · Vaccines · doi:10.3390/vaccines10040575 · Cited by 21
Self-citation
Myocarditis after BNT162b2 and mRNA-1273 COVID-19 vaccination: A report of 7 cases
Ahmed, S. K. (2022) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2022.103657 · Cited by 21
Near real-time surveillance of safety outcomes in US COVID-19 vaccine recipients aged 12 to 64 years
Lloyd, P. C., Hu, M., Wong, H., Shoaibi, A., Zhou, C. K., Lo, A., Amend, K. L., Beachler, D. C., McMahill‐Walraven, C. N., Smith, E. R., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.09.060 · Cited by 21
Antineutrophil Cytoplasmic Antibody-associated Vasculitis after COVID-19 Vaccination with Pfizer-BioNTech
Suzuki, M., Sekiguchi, Y., Sasaki, M., Inaba, S., Oyama, S., Inoue, Y., Warabi, M., Ohashi, K., & Inoshita, S. (2022) · Internal Medicine · doi:10.2169/internalmedicine.9807-22 · Cited by 21
Myocarditis Following COVID-19 Vaccination
Marschner, C., Shaw, K. E., Tijmes, F. S., Fronza, M., Khullar, S., Seidman, M. A., Thavendiranathan, P., Udell, J. A., Wald, R. M., & Hanneman, K. A. (2023) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.08.012 · Cited by 24
An mRNA vaccine against rabies provides strong and durable protection in mice
Li, M., Fang, E., Wang, Y., Shi, L., Li, J., Peng, Q., Li, X., Zhao, D., Liu, X., Liu, X., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1288879 · Cited by 20
Letter to the editor: Autoimmune hepatitis after COVID‐19 vaccination: Need for population‐based epidemiological study
Suzuki, Y., Kakisaka, K., & Takikawa, Y. (2021) · Hepatology · doi:10.1002/hep.32280 · Cited by 20
A Review of the Importance and Relevance of Real-World Data and Real-World Evidence
Parums, D. V. (2025) · Medical Science Monitor · doi:10.12659/msm.951118 · Cited by 19
Proposed Pathogenesis, Characteristics, and Management of COVID-19 mRNA Vaccine-Related Myopericarditis
Hajra, A., Gupta, M., Ghosh, B., Ashish, K., Patel, N., Manek, G., Rai, D., Sreenivasan, J., Goel, A., Lavie, C. J., et al. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-021-00511-8 · Cited by 19
Homologous and Heterologous Anti-COVID-19 Vaccination Does Not Induce New-Onset Formation of Autoantibodies Typically Accompanying Lupus Erythematodes, Rheumatoid Arthritis, Celiac Disease and Antiphospholipid Syndrome
Thurm, C., Reinhold, A., Borucki, K., Kahlfuß, S., Feist, E., Schreiber, J., Reinhold, D., & Schraven, B. L. (2022) · Vaccines · doi:10.3390/vaccines10020333 · Cited by 19
Cardiac magnetic resonance imaging of myocarditis and pericarditis following COVID-19 vaccination: a multicenter collection of 27 cases
Dedda, E. D., Barison, A., Aquaro, G. D., Ismail, T. F., Hua, A. X., Mantini, C., Ricci, F., Pontone, G., Volpe, A., Secchi, F., et al. (2022) · European Radiology · doi:10.1007/s00330-022-08566-0 · Cited by 19
Clinical and Molecular Characterization of a Rare Case of BNT162b2 mRNA COVID-19 Vaccine-Associated Myositis
Magen, E., Mukherjee, S., Bhattacharya, M., Detroja, R., Merzon, E., Blum, I., Livoff, A., Shlapobersky, M., Baum, G., Talisman, R., et al. (2022) · Vaccines · doi:10.3390/vaccines10071135 · Cited by 21
Clinical cardiovascular emergencies and the cellular basis of COVID-19 vaccination: from dream to reality?
Li, Y. E., Wang, S., Reiter, R. J., & Ren, J. T. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.08.026 · Cited by 23
Graves’ Disease Following SARS-CoV-2 Vaccination: A Systematic Review
Patrizio, A., Ferrari, S. M., Elia, G., Ragusa, F., Paparo, S. R., Mazzi, V., Antonelli, A., & Fallahi, P. (2022) · Vaccines · doi:10.3390/vaccines10091445 · Cited by 20
Optimizing Safety Surveillance for COVID-19 Vaccines at the National Pharmacovigilance Centre Lareb: One Year of COVID-19 Vaccine Experience
Oosterhuis, I., Scholl, J. H. G., van Puijenbroek, E., Kant, A. C., & van Hunsel, F. P. A. M. (2022) · Drug Safety · doi:10.1007/s40264-022-01253-5 · Cited by 19
Risk and Benefit of mRNA COVID-19 Vaccines for the Omicron Variant by Age, Sex, and Presence of Comorbidity: A Quality-Adjusted Life Years Analysis
Kitano, T., Thompson, D. A., Engineer, L. D., Dudley, M. Z., & Salmon, D. A. (2023) · American Journal of Epidemiology · doi:10.1093/aje/kwad058 · Cited by 19
COVID-19 Vaccines and Myocarditis: An Overview of Current Evidence
Hromić‐Jahjefendić, A., Sezer, A., Aljabali, A. A. A., Serrano‐Aroca, Á., Tambuwala, M. M., Uversky, V. N., Redwan, E. M. M. M., Barh, D., & Lundstrom, K. H. (2023) · Biomedicines · doi:10.3390/biomedicines11051469 · Cited by 19
Arrhythmias after COVID-19 Vaccination: Have We Left All Stones Unturned?
Cocco, N., Leibundgut, G., Pelliccia, F., Cammalleri, V., Nusca, A., Mangiacapra, F., Cocco, G., Fanale, V., Ussia, G. P., & Grigioni, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210405 · Cited by 21
Physicians' Perspective on Vaccine-Hesitancy at the Beginning of Israel's COVID-19 Vaccination Campaign and Public's Perceptions of Physicians' Knowledge When Recommending the Vaccine to Their Patients: A Cross-Sectional Study
Gesser‐Edelsburg, A., & Keywan, H. B. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.855468 · Cited by 19
Biopsy-Proven Fulminant Myocarditis Requiring Mechanical Circulatory Support Following COVID-19 mRNA Vaccination
Kazama, S., Okumura, T., Kimura, Y., Ito, R., Araki, T., Mizutani, T., Oishi, H., Kuwayama, T., Hiraiwa, H., Kondo, T., et al. (2022) · CJC Open · doi:10.1016/j.cjco.2022.02.004 · Cited by 18
Increased risk of myocarditis and pericarditis and reduced likelihood of severe clinical outcomes associated with COVID-19 vaccination: a cohort study in Lombardy, Italy
Corrao, G., Franchi, M., Cereda, D., Bortolan, F., Leoni, O., Vignati, E., Pavesi, G., & Gori, A. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07823-3 · Cited by 19
COVID-19 Vaccination Did Not Increase the Risk of Potentially Related Serious Adverse Events: 18-Month Cohort Study in an Italian Province
Flacco, M. E., Martellucci, C. A., Soldato, G., Martino, G. D., Carota, R., Benedictis, M. D., Marco, G. D., Parruti, G., Luzio, R. D., Caponetti, A., et al. (2022) · Vaccines · doi:10.3390/vaccines11010031 · Cited by 24
COVID-19 Vaccine Safety First Year Findings in Adolescents
Hesse, E. M., Hause, A. M., Myers, T. R., Su, J. R., Marquez, P., Zhang, B., Cortese, M. M., Thames-Allen, A., Curtis, C. R., Maloney, S. A., et al. (2023) · PEDIATRICS · doi:10.1542/peds.2022-060295 · Cited by 19
Safety of BA.4-5 or BA.1 bivalent mRNA booster vaccines: nationwide cohort study
Andersson, N. W., Thiesson, E. M., Hansen, J. V., & Hviid, A. P. (2023) · BMJ · doi:10.1136/bmj-2023-075015 · Cited by 21
Comparative safety analysis of mRNA and adenoviral vector COVID-19 vaccines: a nationwide cohort study using an emulated target trial approach
Choi, M. J., Na, Y., Hyun, H., Nham, E., Yoon, J. G., Seong, H., Seo, Y. B., Choi, W. S., Song, J. Y., Kim, D. W., et al. (2023) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2023.12.010 · Cited by 19
Myocarditis or Pericarditis Following the COVID-19 Vaccination in Adolescents: A Systematic Review
Li, M., Wang, X., Feng, J., Feng, Z., Li, W., & Ya, B. (2022) · Vaccines · doi:10.3390/vaccines10081316 · Cited by 18
Inhibition of CXCL10 and IFN-γ ameliorates myocarditis in preclinical models of SARS-CoV-2 mRNA vaccination
Cao, X., Manhas, A., Chen, Y. M., Caudal, A., Mondéjar‐Parreño, G., Zhu, W., Liu, W., Kong, X., Zeng, W., Liu, L., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adq0143 · Cited by 19
Meta-Analysis of Risk of Myocarditis After Messenger RNA COVID-19 Vaccine
Wang, M., Wen, W., Zhou, M., Wang, C., & Feng, Z.-H. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2021.12.007 · Cited by 17
It Takes Two to Tango: How the COVID-19 Vaccination Campaign in Israel Was Framed by the Health Ministry vs. the Television News
Gesser‐Edelsburg, A., Hijazi, R., & Cohen, R. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.887579 · Cited by 22
Type 1 Diabetes Mellitus Associated with Nivolumab after Second SARS-CoV-2 Vaccination, Japan
Sato, T., Kodama, S., Kaneko, K., Imai, J., & Katagiri, H. (2022) · Emerging infectious diseases · doi:10.3201/eid2807.220127 · Cited by 17
Distinct Features of Vascular Diseases in COVID-19
Ceasovschih, A., Șorodoc, V., Shor, A., Haliga, R. E., Roth, L., Lionte, C., Aursulesei, V. O., Sîrbu, O., Culiș, N., Shapieva, A. N., et al. (2023) · Journal of Inflammation Research · doi:10.2147/jir.s417691 · Cited by 18
Collaboration within the global vaccine safety surveillance ecosystem during the COVID-19 pandemic: lessons learnt and key recommendations from the COVAX Vaccine Safety Working Group
Chandler, R. E., Balakrishnan, M. R., Brasseur, D. J., Bryan, P. T., Espié, E., Hartmann, K., Jouquelet‐Royer, C., Milligan, J., Nesbitt, L., Pal, S. N., et al. (2024) · BMJ Global Health · doi:10.1136/bmjgh-2023-014544 · Cited by 17
Pathological findings of clinically suspected myocarditis temporally associated with COVID ‐19 vaccination
Yamamoto, M., Tajiri, K., Ayuzawa, S., & Ieda, M. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2523 · Cited by 17
Major severe acute respiratory coronavirus-2 (SARS-CoV-2) vaccine-associated adverse effects; benefits outweigh the risks
Esmaeilzadeh, A., Maleki, A. J., Moradi, A., Siahmansouri, A., Barhaghtalab, M. J. Y., Karami, P., & Elahi, R. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2116008 · Cited by 17
A Bayesian network analysis quantifying risks versus benefits of the Pfizer COVID-19 vaccine in Australia
Sinclair, J. E., Mayfield, H. J., Short, K. R., Brown, S. J., Puranik, R., Mengersen, K. L., Litt, J. C. B., & Lau, C. L. (2022) · npj Vaccines · doi:10.1038/s41541-022-00517-6 · Cited by 18
There is nothing exempt from the peril of mutation – The Omicron spike
Behl, T., Kaur, I., Sehgal, A., Singh, S., Sharma, N., Anwer, M. K., Makeen, H. A., Albratty, M., Alhazmi, H. A., Bhatia, S., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112756 · Cited by 16
Disentangling a Thorny Issue: Myocarditis and Pericarditis Post COVID-19 and Following mRNA COVID-19 Vaccines
Rafaniello, C., Gaio, M., Zinzi, A., Sullo, M. G., Liguori, V., Ferraro, M., Petronzelli, F., Felicetti, P., Marchione, P., Marra, A. R., et al. (2022) · Pharmaceuticals · doi:10.3390/ph15050525 · Cited by 16
Demographic and Clinical Factors Associated With Anti–SARS-CoV-2 Antibody Levels After 2 BNT162b2 mRNA Vaccine Doses
Nam, S. Y., Jeon, S. W., Lee, H. S., Lim, H. J., Lee, D. W., & Yoo, S. S. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.12996 · Cited by 15
mRNA (BNT162b2) and Inactivated (CoronaVac) COVID-19 Vaccination and Risk of Adverse Events and Acute Diabetic Complications in Patients with Type 2 Diabetes Mellitus: A Population-Based Study
Wan, E. Y. F., Chui, C. S. L., Mok, A. H. Y., Xu, W., Yan, V. K. C., Lai, F. T. T., Li, X., Wong, C. K. H., Chan, E. W., Lui, D. T. W., et al. (2022) · Drug Safety · doi:10.1007/s40264-022-01228-6 · Cited by 17
Long term follow up and outcomes of Covid-19 vaccine associated myocarditis in Victoria, Australia: A clinical surveillance study
Shenton, P., Schrader, S., Smith, J., Alafaci, A., Cox, N. R., Taylor, A. J., Hare, J., Jones, B., Crawford, N. W., Buttery, J. P., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.12.070 · Cited by 17
Increased rates of idiopathic inflammatory myopathies during the COVID-19 pandemic: a single-centre experience
Kharouf, F., Kenig, A., Bohbot, E., Rubin, L., Peleg, H., & Shamriz, O. (2023) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/970881 · Cited by 16
mRNA vaccines against COVID‐19: a showcase for the importance of microbial biotechnology
Brüssow, H. (2021) · Microbial Biotechnology · doi:10.1111/1751-7915.13974 · Cited by 16
Cardiomyopathy Associated with Anti-SARS-CoV-2 Vaccination: What Do We Know?
Parra-Lucares, A., Toro, L., Weitz-Muñoz, S., & Ramos, C. (2021) · Viruses · doi:10.3390/v13122493 · Cited by 15
A Case Series of Myocarditis Following Third (Booster) Dose of COVID-19 Vaccination: Magnetic Resonance Imaging Study
Shiyovich, A., Witberg, G., Aviv, Y., Kornowski, R., & Hamdan, A. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.839090 · Cited by 15
Rare Adverse Events Associated with BNT162b2 mRNA Vaccine (Pfizer-BioNTech): A Review of Large-Scale, Controlled Surveillance Studies
Yong, S. J., Halim, A., Halim, M., Mutair, A. S. A., Alhumaid, S., AlSihati, J., Albayat, H., Alsaeed, M., Garout, M. A., Azmi, R. A., et al. (2022) · Vaccines · doi:10.3390/vaccines10071067 · Cited by 15
A case series of dermatomyositis following SARS-CoV-2 vaccination
Chan, A. R., Tervaert, J. W. C., Redmond, D., Yacyshyn, E., Ferrara, G., Hwang, P. M., Osman, M., & Gniadecki, R. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1013378 · Cited by 14
Myocarditis and Cardiac Complications Associated With COVID-19 and mRNA Vaccination: A Pragmatic Narrative Review to Guide Clinical Practice
Holland, D. J., Blazak, P., Martin, J., Broom, J. K., Poulter, R. S., & Stanton, T. (2022) · Heart Lung and Circulation · doi:10.1016/j.hlc.2022.03.003 · Cited by 18
Messenger ribonucleic acid vaccines against infectious diseases: current concepts and future prospects
Edwards, D. K., & Carfı́, A. (2022) · Current Opinion in Immunology · doi:10.1016/j.coi.2022.102214 · Cited by 18
New insights into human immune memory from SARS‐CoV ‐2 infection and vaccination
Hartley, G. E., Edwards, E. S. J., O’Hehir, R. E., & van Zelm, M. C. (2022) · Allergy · doi:10.1111/all.15502 · Cited by 15
Myocarditis After BNT162b2 COVID-19 Third Booster Vaccine in Israel
Mevorach, D., Anis, E., Cedar, N., Hasin, T., Bromberg, M., Goldberg, L., Levi, N., Perzon, O., Magadle, N., Barhoum, B., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.060961 · Cited by 16
Self-citation
BNT162b2 COVID-19 vaccination uptake, safety, effectiveness and waning in children and young people aged 12–17 years in Scotland
Rudan, I., Millington, T., Antal, K., Grange, Z., Fenton, L., Sullivan, C. B., Buelo, A., Wood, R., Woolford, L., Swann, O. V., et al. (2022) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2022.100513 · Cited by 15
Myopericarditis Associated with the Novavax COVID-19 Vaccine (NVX-CoV2373): A Retrospective Analysis of Individual Case Safety Reports from VigiBase
Saint-Gerons, D. M., Ibarz, M. T., Castro, J. L., Forés-Martos, J., & Tabarés‐Seisdedos, R. (2023) · Drugs - Real World Outcomes · doi:10.1007/s40801-023-00355-5 · Cited by 14
Clinical Features of Patients Presenting to the Emergency Department With Cardiovascular Adverse Reactions After COVID-19 mRNA Vaccination
Oh, T.-H., Woo, S. H., Hong, S., Lee, C., Lee, W. J., & Jeong, S. (2022) · Journal of Korean Medical Science · doi:10.3346/jkms.2022.37.e73 · Cited by 14
A Case Series of Ketoacidosis After Coronavirus Disease 2019 Vaccination in Patients With Type 1 Diabetes
Yakou, F., Saburi, M., Hirose, A., Akaoka, H., Hirota, Y., Kobayashi, T., Awane, N., Asahi, N., Amagawa, T., Ozawa, S., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.840580 · Cited by 14
Rare Heterogeneous Adverse Events Associated with mRNA-Based COVID-19 Vaccines: A Systematic Review
Oueijan, R. I., Hill, O. R., Ahiawodzi, P. D., Fasinu, P. S., & Thompson, D. K. (2022) · Medicines · doi:10.3390/medicines9080043 · Cited by 14
Myocarditis Following COVID-19 Vaccination
Marschner, C., Shaw, K. E., Tijmes, F. S., Fronza, M., Khullar, S., Seidman, M. A., Thavendiranathan, P., Udell, J. A., Wald, R. M., & Hanneman, K. A. (2022) · Cardiology Clinics · doi:10.1016/j.ccl.2022.05.002 · Cited by 14
The effect of the BNT162b2 vaccine on antinuclear antibody and antiphospholipid antibody levels
Noureldine, H. A., Maamari, J., Helou, M. O. E., Chedid, G., Farra, A., Husni, R., & Mokhbat, J. (2022) · Immunologic Research · doi:10.1007/s12026-022-09309-5 · Cited by 14
A Prospective Study on Myocardial Injury After BNT162b2 mRNA COVID-19 Fourth Dose Vaccination in Healthy Persons
Levi, N., Moravsky, G., Weitsman, T., Amsalem, I., Itach, S. B., Algur, N., Lapidus, I., Mitz, O., Glikson, M., Weil‐Weiner, Y., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2687 · Cited by 14
Self-citation
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein VaccinePreprint
Dayan, G. H., Rouphael, N., Walsh, S. R., Chen, A.-Y., Grunenberg, N., Allen, M., Antony, J., Asante, K., Bhate, A., Beresnev, T. H., et al. (2022) · medRxiv · doi:10.1101/2022.12.05.22282933 · Cited by 13
Meeting the Challenges of Myocarditis: New Opportunities for Prevention, Detection, and Intervention—A Report from the 2021 National Heart, Lung, and Blood Institute Workshop
Čiháková, D., Shi, Y., Adhikari, B., Bandettini, W. P., Cunningham, M. W., Danthi, N., Friedrich, M. G., Liu, P., Longacre, L. S., Mann, D. L., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195721 · Cited by 13
Case Report: Myocarditis After COVID-19 Vaccination – Case Series and Literature Review
Nunn, S., Kersten, J., Tadić, M., Wolf, A., Gonska, B., Hüll, E., Dietenberger, H., Rottbauer, W., & Buckert, D. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.836620 · Cited by 13
COVID-19 and the heart
Xanthopoulos, A. V., Bourazana, A., Giamouzis, G., Skoularigki, E., Dimos, A. K., Zagouras, A., Papamichalis, M., Leventis, I., Magouliotis, D. E., Triposkiadis, F. K., et al. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i28.9970 · Cited by 13
Safety after BBIBP-CorV (Sinopharm) COVID-19 Vaccine in Adolescents Aged 10–17 Years in Thailand
Thonginnetra, S., Tawinprai, K., Niemsorn, K., Promsena, P., Tandhansakul, M., Kasemlawan, N., Ruangkijpaisal, N., Banomyong, N., Phattraprayoon, N., Rangkakulnuwat, P., et al. (2022) · Vaccines · doi:10.3390/vaccines10101765 · Cited by 13
COVID-19 Vaccine Safety Technical (VaST) Work Group: Enhancing vaccine safety monitoring during the pandemic
Markowitz, L. E., HOPKINS, R. H., Broder, K. R., Lee, G. M., Edwards, K. M., Daley, M. F., Jackson, L. A., Nelson, J. C., Riley, L. E., McNally, V. V., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2023.12.059 · Cited by 13
Fulminant myocarditis after the second dose of COVID‐19 mRNA vaccination
Oka, A., Sudo, Y., Miyoshi, T., Ozaki, M., Kimura, Y., Takagi, W., Ugawa, S., Okada, T., Nosaka, K., & Doi, M. (2022) · Clinical Case Reports · doi:10.1002/ccr3.5378 · Cited by 11
Implication of microRNA as a potential biomarker of myocarditis
Oh, J.-H., Kim, G. B., & Seok, H. (2022) · Korean Journal of Pediatrics · doi:10.3345/cep.2021.01802 · Cited by 15
Myocarditis after vaccination against covid-19
Gellad, W. F. (2021) · BMJ · doi:10.1136/bmj.n3090 · Cited by 13
Sports, Myocarditis and COVID-19: Diagnostics, Prevention and Return-to-play Strategies
Schmidt, T., Bjarnason‐Wehrens, B., Zacher, J., Predel, H., & Reiss, N. (2022) · International Journal of Sports Medicine · doi:10.1055/a-1810-5314 · Cited by 12

Authors: Mevorach, D., Anis, E., Cedar, N., Bromberg, M., Haas, E. J., Nadir, E., Olsha-Castell, S., Arad, D., Hasin, T., Levi, N., Asleh, R., Amir, O., Meir, K., Cohen, D., Dichtiar, R., Novick, D., Hershkovitz, Y., Dagan, R., Leitersdorf, I., Ben-Ami, R., Miskin, I., Saliba, W., Muhsen, K., Levi, Y., Green, M. S., Keinan-Boker, L., & Alroy-Preis, S.
Affiliations: Bar-Ilan University (IL)
From the Department of Internal Medicine B, Division of Immunology–Rheumatology, and Wohl Institute for Translational Medicine (D.M.) and the Departments of Cardiology (R.A., O.A.), Pathology (K. Meir), and Radiology (D.C.), Hadassah Medical Center, Braun School of Public Health (E.A.), Jesselson Integrated Heart Center, Shaare Zedek Medical Center (T.H., N.L.), and the Department of Family Medicine (I.M.), Faculty of Medicine, Hebrew University of Jerusalem, the Divisions of Epidemiology (E.A., N.C., E.J.H., E.N.), Patient Safety (S.O.-C., D.A.), and Medicine (I.L.), Israeli Ministry of Health (M.B., R. Dichtiar, D.N., Y.H., Y.L., L.K.-B., S.A.-P.), and Clalit Health Services (E.N., I.M.), Jerusalem, Israel Center for Disease Control, and Azrieli Faculty of Medicine, Bar-Ilan University (O.A.), Ramat Gan, the Department of Epidemiology and Preventive Medicine, School of Public Health (M.B., K. Muhsen), and Tel Aviv Sourasky Medical Center (R.B.-A.), Tel Aviv University, Tel Aviv, Ben Gurion University of ...
Corresponding author: Alroy-Preis, Sharon
ORCID: Mevorach, Dror
Bromberg, Michal
Haas, Eric J.
Levi, Nir
Dagan, Ron
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2021-12-02
Volume: 385
Issue: 23
Pages: 2140-2149
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa2109730
PMC: PMC8531987
OpenAlex: W3204791524
Cited by: 599
References: 7
Citations by year: 2026: 29 · 2025: 39 · 2024: 84 · 2023: 125 · 2022: 280 · 2021: 41
FWCI: 88.83
Type: journal article
Language: en
Open access: green
europepmc.org
Locations: New England Journal of Medicine (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Keywords: myocarditis, BNT162b2 mRNA vaccine, COVID-19 vaccination, vaccine adverse events, incidence, standardized incidence ratio, risk difference, second vaccine dose, young men, Israel, active surveillance, adverse event reporting, vaccine safety surveillance, COVID-19 mortality, SARS-CoV-2 variants, Omicron variant
MeSH terms: COVID-19, BNT162 Vaccine, Adolescent, Adult, Echocardiography, Female, Hospitalization, Humans, Israel, Male, Middle Aged, Myocarditis, Retrospective Studies, Comorbidity, Incidence, Age Distribution, Sex Distribution, Kaplan-Meier Estimate, Young Adult, Patient Acuity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks